Thalys Medical Technology Group Corporation(603716) (SH 603716, closing price: RMB 20.65) announced on January 20 that Wuhan Thalis Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, signed the sales partner agreement with ate gold kuyumculuk on January 20, 2022. Ate gold kuyumculuk purchased $20 million from Thalis biotechnology for the first time, The amount of the first trial order is US $1 million. At present, the other party has paid a deposit of US $100000.
The 2020 annual report shows that the main businesses of Thalys Medical Technology Group Corporation(603716) are commerce and industry, accounting for 97.54% and 2.46% of revenue respectively.
The chairman of Thalys Medical Technology Group Corporation(603716) is Wen Wei, male, 53, with a master’s degree background; The general manager is Wang Zheng, male, 55 years old, with a master’s degree background.
